Obesity Medicines Are Disruptive Innovation
A commentary in Nature Medicine argues that new anti-obesity drugs represent a disruptive innovation requiring health system adaptation, with the author
New anti-obesity medications represent a disruptive innovation that will force health systems to adapt, according to a commentary published in Nature Medicine in 2026. The article's author, Naveed Sattar, has received consulting and speaking fees from numerous drugmakers in the field.
Sattar's perspective piece, titled "Obesity medicines as disruptive innovation," frames the latest generation of weight-loss drugs as a pivotal shift. He contends that their efficacy and growing use will necessitate significant changes in how healthcare is structured and delivered.
Pharmaceutical Industry Ties
The commentary includes a standard disclosure of competing interests. Naveed Sattar reports having consulted for or received speaker honoraria from a wide range of companies. This list provides context for the author's expertise and potential financial associations within the industry he is discussing.
According to the disclosure, these companies include:
Publication and Access Details
The article was published as part of the 2026 volume of Nature Medicine. It is subject to the journal's standard access model, which includes various purchase and subscription options for readers.
Individual access to the full article can be purchased directly. Institutional subscriptions provide broader access to Nature and dozens of other journals in its portfolio.
The commentary is published under standard copyright and permissions guidelines. It carries a digital object identifier (DOI) for permanent citation.
Core Argument on System Adaptation
The central thesis presented is that health systems are unprepared for the scale of change brought by effective obesity pharmacotherapies. Sattar does not elaborate on specific adaptation strategies in the available preview text. The argument rests on the classification of these treatments as genuinely disruptive, implying they will challenge existing clinical and economic models of care.
This perspective is offered as a preview of subscription content from the journal. The full details of Sattar's analysis on the necessary adaptations are behind the publication's paywall.
The article serves as a high-level call to action for policymakers and health system planners. It signals a belief that the arrival of these drugs is not merely an incremental advance but a fundamental shift requiring proactive planning. The published version of the article in Nature Medicine is now part of the scientific record for 2026.
